Summary
Daewoong Pharmaceutical Co Ltd (Daewoong Pharma) is one of the leading manufacturers and distributors of prescription drugs in South Korea. It offers prescription drugs, quasi drugs, medical devices, cosmetics, health foods and APIs. The company produces products in the forms of tablets, capsules, ointments, injections, liquids and sprays. It offers its products for the therapeutic conditions of bone and joint diseases, cardiovascular diseases, central nervous system diseases, circulatory system, dermatological, gastrointestinal, and respiratory remedies, among others. The company also carries out development and commercialization of products through in-licensing, co-marketing and co-promotion. It operates across Asia including Indonesia, China, Vietnam, Thailand and India; and the US. Daewoong Pharma is headquartered in Seoul, South Korea.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope
Reasons to Buy
Note: Some sections may be missing if data is unavailable for the company
Daewoong Pharmaceutical Co Ltd (Daewoong Pharma) is one of the leading manufacturers and distributors of prescription drugs in South Korea. It offers prescription drugs, quasi drugs, medical devices, cosmetics, health foods and APIs. The company produces products in the forms of tablets, capsules, ointments, injections, liquids and sprays. It offers its products for the therapeutic conditions of bone and joint diseases, cardiovascular diseases, central nervous system diseases, circulatory system, dermatological, gastrointestinal, and respiratory remedies, among others. The company also carries out development and commercialization of products through in-licensing, co-marketing and co-promotion. It operates across Asia including Indonesia, China, Vietnam, Thailand and India; and the US. Daewoong Pharma is headquartered in Seoul, South Korea.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Daewoong Pharmaceutical Co Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Daewoong Pharmaceutical Co Ltd Company OverviewDaewoong Pharmaceutical Co Ltd Company Snapshot
Daewoong Pharmaceutical Co Ltd Pipeline Products and Ongoing Clinical Trials Overview
Daewoong Pharmaceutical Co Ltd – Pipeline Analysis Overview
Business Description
Daewoong Pharmaceutical Co Ltd - Key Facts
Daewoong Pharmaceutical Co Ltd - Major Products and Services
Daewoong Pharmaceutical Co Ltd Pipeline Products by Development Stage
Daewoong Pharmaceutical Co Ltd Ongoing Clinical Trials by Trial Status
Daewoong Pharmaceutical Co Ltd Pipeline Products Overview
Donepezil Patch
Donepezil Patch Product Overview
Iodixanol Contrast Medium
Iodixanol Contrast Medium Product Overview
Ioversol Contrast Medium
Ioversol Contrast Medium Product Overview
Mediclore
Mediclore Product Overview
Mediclore Clinical Trial
NOVOSIS - DENT
NOVOSIS - DENT Product Overview
NOVOSIS - Spinal Fusion
NOVOSIS - Spinal Fusion Product Overview
NOVOSIS - Spinal Fusion Clinical Trial
Daewoong Pharmaceutical Co Ltd - Key Competitors
Daewoong Pharmaceutical Co Ltd - Key Employees
Daewoong Pharmaceutical Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Daewoong Pharmaceutical Co Ltd, Recent Developments
May 26, 2016: Daewoong Bio ‘UDCA’ passes EDQM (European Directorate for the Quality of Medicines & Healthcare) inspection
Apr 06, 2016: Daewoong Pharmaceuticals signs export contract and MOU with Taiwanese and Malaysian pharmaceutical companies
Dec 14, 2014: Daewoong Pharmaceutical and Daewoong Bio co-participates in CPhI Worldwide
Dec 03, 2014: Daewoong Pharmaceutical’s Ursa completed registration in Georgia
Nov 03, 2014: Daewoong Pharmaceutical established Liaoning Research Institute, its local research arm in China
Oct 24, 2014: Lee Jong-wook, President of Daewoong Pharmaceutical, was honored with the grand prize in Korea New Drug Award of Pharmaceutical Society of Korea
Sep 30, 2014: Daewoong Pharmaceutical rose to the position of undisputed No. 1 leader in terms of pharmaceutical production last year
Sep 24, 2014: Daewoong Pharmaceutical was honored with the Prize of the 'Most Trusted Company in 2014`
Mar 18, 2014: Daewoong Pharmaceutical rolls out ‘Easyderm Beauty’, the spot-type wet dressing for treating the skin troubles
Dec 30, 2011: New-Concept Medical Equipment ‘Novosis’ Clinical Test Started In Orthopedics In Addition To Dentistry
Appendix
Methodology
About
Contact Us
Disclaimer
List of Tables
Daewoong Pharmaceutical Co Ltd Pipeline Products and Ongoing Clinical Trials Overview
Daewoong Pharmaceutical Co Ltd Pipeline Products by Equipment Type
Daewoong Pharmaceutical Co Ltd Pipeline Products by Indication
Daewoong Pharmaceutical Co Ltd Ongoing Clinical Trials by Trial Status
Daewoong Pharmaceutical Co Ltd, Key Facts
Daewoong Pharmaceutical Co Ltd, Major Products and Services
Daewoong Pharmaceutical Co Ltd Number of Pipeline Products by Development Stage
Daewoong Pharmaceutical Co Ltd Pipeline Products Summary by Development Stage
Daewoong Pharmaceutical Co Ltd Ongoing Clinical Trials by Trial Status
Daewoong Pharmaceutical Co Ltd Ongoing Clinical Trials Summary
Donepezil Patch - Product Status
Donepezil Patch - Product Description
Iodixanol Contrast Medium - Product Status
Iodixanol Contrast Medium - Product Description
Ioversol Contrast Medium - Product Status
Ioversol Contrast Medium - Product Description
Mediclore - Product Status
Mediclore - Product Description
Mediclore - A Randomized, Single-blind, Multi-center, Phase III Clinical Trail to Evaluate the Efficacy and Safety of Adhesion Barrier Mediclore Versus no Treatment in Patients with Total Thyroidectomy
Mediclore - A Randomized, Single-blind, Multi-center, Phase III Clinical Trail to Evaluate the Efficacy and Safety of Adhesion Barrier Mediclore Versus no Treatment in Patients with Total Thyroidectomy
Mediclore - Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore) after Axillary Dissection for Breast Cancer a Multicenter Double-blinded, Randomized Study
Mediclore - Evaluate Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan (Mediclore) for Intraperitoneal Adhesion in Patient with Gynecological Surgery, a Multicenter Single-blinded, Randomized Study
Mediclore - To Evaluate Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore) after Intrauterine Surgery in Patient with Gynecological Disease, a Multicenter, Randomized, Double- blinded Study
NOVOSIS - DENT - Product Status
NOVOSIS - DENT - Product Description
NOVOSIS - Spinal Fusion - Product Status
NOVOSIS - Spinal Fusion - Product Description
NOVOSIS - Spinal Fusion - The Clinical Study to Evaluate the Efficacy and Safety of Novosis in Posterolateral Fusion
Daewoong Pharmaceutical Co Ltd, Key Employees
Daewoong Pharmaceutical Co Ltd, Other Locations
Daewoong Pharmaceutical Co Ltd, Subsidiaries
Glossary
List of Figures
Daewoong Pharmaceutical Co Ltd Pipeline Products by Equipment Type
Daewoong Pharmaceutical Co Ltd Pipeline Products by Development Stage
Daewoong Pharmaceutical Co Ltd Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Yungjin Pharm Co Ltd
- Yuhan Corp
- Sam Chun Dang Pharm Co Ltd
- Huons Global Co Ltd
- GC Pharma
- Dong-A Socio Holdings Co Ltd
- DAE HWA Pharmaceutical Co Ltd
